top of page
Search

Hidden Consequences of COVID-19: Why Small Biotechs Can't Just Wait This One Out
By C. Simone Fishburn, Editor In Chief It’s still anyone’s guess as to how long the COVID-19 outbreak will take to peak, let alone wane...


Bayer’s Finerenone Use Will Face Off With SGLT2 Inhibitors
By Manasi Vaidya, Reporter, New York Sodium-glucose cotransporter-2 (SGLT2) inhibitors’ growing prominence in diabetic kidney disease...


Novavax’s NanoFlu Has Tepid Expert Market Forecasts in Influenza Versus Sanofi’s Fluzone
By Bernarda Tundzhay, Reporter, London Novavax’s (NASDAQ:NVAX) NanoFlu influenza vaccine has garnered lukewarm expert predictions for its...


Is Tau the New Amyloid?
By Selina Koch, Senior Editor After finally getting the message that they need to look beyond amyloid to treat Alzheimer’s disease,...


Novartis’ Zolgensma has First-Line Potential in Spinal Muscular Atrophy (SMA)
Novartis’ (SIX:NOVN) Zolgensma (onasemnogene abeparvovec-xioi) has strong potential to be used as a first-line treatment in spinal...


BobVie’s Orilissa and Myovant’s Relugolix Expected to Face Similar Payer Scrutiny in Uterine Fibroid
The reimbursement experience physicians are having with AbbVie’s (NYSE:ABBV) Orilissa (elagolix) in endometriosis-related pain is likely...

Aclaris' Phase II Results for ATI-502 and ATI - 501 in Alopecia May Lack Cosmetic Significance
Aclaris Therapeutics’ (NASDAQ:ACRS) Phase II ATI-502 for alopecia areata (AA) and Phase II for ATI-501 for AA, alopecia universalis (AU)...


Aldeyra's Reproxalap has Experts Mixed on Seasonal Allergic Conjunctivitis Focus in Phase III
Aldeyra Therapeutics’ (NASDAQ:ALDX) focus on seasonal allergies in its Phase III study of reproxalap in allergic conjunctivitis has three...


Immunomedics’ Sacituzumab Has Insufficient Dataset to Pursue Accelerated Approval
Immunomedics’ (NASDAQ:IMMU) Phase I/ II sacituzumab govitecan hormone receptor positive (HR+) Her2-negative breast cancer data may not be...

Eisai's Lenvima for First-line HCC Is Approvable but Noninferiority Data to SOC May Slow Uptake
Eisai’s (TYO:4523) Lenvima (lenvatinib) has a clear path to approval in first-line hepatocellular carcinoma (HCC), with its positive...
bottom of page